RARE

Ultragenyx Pharmaceutical (RARE) shares surged roughly 12.6% to 13% after the FDA approved what headlines describe as the first Sanfilippo gene therapy, a move Barron's calls a landmark approval. One headline notes the stock had previously suffered a catastrophic 44% dive and has only partially reversed it. No Reddit discussion was supplied, so retail sentiment cannot be assessed.

Generated only from linked headlines and Reddit titles. Verify the underlying sources.